Article

En ligne (disponible) - Article
Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care / CHEUNG, Angela M ; FEIG, Denice S. ; KAPRAL, Moira ; DIAZ-GRANADOS, Natalia ; DODIN, Sylvie ; Canadian task force on preventive health care.
CMAJ : Canadian medical association journal, 2004, vol. 170 (11), p.1665-1667.

http://www.cmaj.ca/content/170/11/1665.full.pdf
Droits d'auteur : Cette oeuvre est protégée par un droit d'auteur. Elle ne peut être reproduite qu'à des fins d'études privées ou de recherche et seulement si la source est mentionnée.

Lieux géographiques
: Canada

Mots-clés principaux
:
Fracture
Postménopause
Ostéoporose
Prévention

Mots-clés secondaires : Hormonothérapie ; Facteur de risque

Résumé :

Une version allongée de cet article est disponible à : http://www.cmaj.ca/content/suppl/2004/05/21/170.11.1665.DC1/170-11-1665.pdf

Recommandations :
* The Canadian Task Force on Preventive Health Care concludes that there is fair evidence to recommend screening postmenopausal women to prevent fragility fractures (no or low trauma fractures) (grade B recommendation). Although there is no direct evidence that screening reduces fractures, there is good evidence that screening is effective in identifying postmenopausal women with low bone mineral density and that treating osteoporosis can reduce the risk of fractures in this population (grade A recommendation).
* For women who screen positive for osteoporosis, there is good to fair evidence that therapy with alendronate, risedronate or raloxifene prevents osteoporotic fractures (grade A to B recommendation).
* For women with severe osteoporosis (osteoporosis plus at least 1 fragility fracture), there is good to fair evidence to recommend the use of alendronate, risedronate, parathyroid hormone (limited duration), raloxifene, etidronate and oral pamidronate therapy (grade A to B recommendation). If none of these drugs is tolerated, hormone replacement therapy
(HRT) or calcitonin can be considered. (In a recent position statement, the task force recommended against combined estrogen­progestin therapy as well as unopposed estrogen therapy for the primary prevention of chronic diseases [grade D recommendation].3)
* For women without documented osteoporosis, there is fair evidence that calcium and vitamin D supplementation alone prevents osteoporotic fractures (grade B recommendation). There
is fair evidence that combined estrogen­progestin therapy decreases the incidence of total, hip and nonvertebral fractures; however, for most women the risks may outweigh the benefits
(grade D recommendation). (As noted above, the task force recently recommended against HRT for the primary prevention of chronic diseases [grade D recommendation].3)

Langue : Anglais
Doc n° : 27953
NumRec : 5814303
Voir aussi
 

       

  Copier Permanent URL de cette page Ajouter cette page

     

disponible
Réserver
Pour réserver ce document, vous devez d'abord vous connecter


Aller vers :   IUGM    Fondation IUGM   Centre de recherche IUGM